<DOC>
	<DOCNO>NCT03105609</DOCNO>
	<brief_summary>Clinical trial investigate role hyperspectral imaging management patient undergo standard clinical treatment naive neovascular choroidal membrane age-related macular degeneration .</brief_summary>
	<brief_title>Enhancing Lucentis ( Ranibizumab ) Management Choroidal Neovascular Membranes With Hyperspectral Imaging</brief_title>
	<detailed_description>Observational trial patient choroidal neovascular membrane treat Lucentis . Exploration validation new form retinal imaging call hyperspectral imaging . Inclusion : Patients meet eligibility criterion FFA diagnosis diagnose suspected exudative CNV OCT. ( n=100 eye ) Procedure : Monthly dos Lucentis . OCT scan take prior injection . HSI image take baseline 9-month time point . Time frame : 6 month recruitment + 12 month follow-up + 6 month analysis . All recruit patient receive monthly dos Lucentis per CMBS-approved protocol allow comparison publish study . Lucentis administer accordance publish standard practice . OCT scan take prior injection . HSI image take baseline , three month 9-month time point</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Provide sign date informed consent form Willing comply study procedure available duration study Male female , aged 5080 In sufficiently good general health able FFA CNV diagnose OCT Vision equal well 6/60 study eye No prior treatment study eye antiVEGF medication Exclusion Criteria Significant medium opacity . Known allergic reaction component study product ( ) . Anything would place individual increase risk preclude individual 's full compliance completion study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hyperspectral imaging , Ranibizumab</keyword>
</DOC>